Personalized treatment of early-stage non-small-cell lung cancer: The challenging role of EGFR inhibitors

Mariacarmela Santarpia, Giuseppe Altavilla, Vincenzo Pitini, Rafael Rosell

Research output: Contribution to journalArticle

Abstract

Adjuvant cisplatin-based chemotherapy significantly improves outcomes of completely resected early-stage non-small-cell lung cancer (NSCLC) patients. However, its effect on overall survival is limited and may be unsuitable for many patients due to toxicity. Targeted therapies and individualization of adjuvant treatment offer the potential to improve curability and extend survival of these patients while decreasing toxicity. Here we review Phase II and III studies examining the role of EGF receptor inhibitors, including tyrosine kinase inhibitors and the monoclonal antibody cetuximab, as adjuvant therapy in resected patients or as part of multimodality treatment for stage III NSCLC. Recent results from genotype-directed adjuvant tyrosine kinase inhibitors trials including early-stage NSCLC patients with EGFR mutations are promising, but more data are needed to support their use in this setting.

Original languageEnglish
Pages (from-to)1259-1274
Number of pages16
JournalFuture Oncology
Volume11
Issue number8
DOIs
Publication statusPublished - Apr 1 2015

    Fingerprint

Keywords

  • adjuvant therapy
  • EGF receptor inhibitors
  • EGFR mutations
  • non-small-cell lung cancer
  • NSCLC
  • personalized treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this